Association between CYP2C19 genotype and the additional effect of cilostazol to clopidogrel resistance in neuroendovascular therapy.

about

Association between CYP2C19 genotype and the additional effect of cilostazol to clopidogrel resistance in neuroendovascular therapy.

Item

http://www.wikidata.org/entity/Q55197889

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Association between CYP2C19 ge ...... in neuroendovascular therapy.

@en

Association between CYP2C19 ge ...... in neuroendovascular therapy.

@nl

type

Item

label

Association between CYP2C19 ge ...... in neuroendovascular therapy.

@en

Association between CYP2C19 ge ...... in neuroendovascular therapy.

@nl

prefLabel

Association between CYP2C19 ge ...... in neuroendovascular therapy.

@en

Association between CYP2C19 ge ...... in neuroendovascular therapy.

@nl

P1476

Association between CYP2C19 ge ...... in neuroendovascular therapy.

@en

P2093

Hayato Tajima

http://www.w3.org/2001/XMLSchema#string

Kazunori Shintai

http://www.w3.org/2001/XMLSchema#string

Kiyofumi Yamada

http://www.w3.org/2001/XMLSchema#string

Masahiro Nishihori

http://www.w3.org/2001/XMLSchema#string

Masashi Ito

http://www.w3.org/2001/XMLSchema#string

Noriaki Matsubara

http://www.w3.org/2001/XMLSchema#string

Shigeru Miyachi

http://www.w3.org/2001/XMLSchema#string

Sho Okamoto

http://www.w3.org/2001/XMLSchema#string

Takashi Izumi

http://www.w3.org/2001/XMLSchema#string

Tasuku Imai

http://www.w3.org/2001/XMLSchema#string

P2860

Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: the VERIfy Thrombosis risk ASsessment (VERITAS) study

Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial.

Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.

Cytochrome CYP2C19 polymorphism and risk of adverse clinical events in clopidogrel-treated patients: a meta-analysis based on 23,035 subjects.

Significance of clopidogrel resistance related to the stent-assisted angioplasty in patients with atherosclerotic cerebrovascular disease.

Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy.

Cilostazol-based triple antiplatelet therapy compared to dual antiplatelet therapy in patients with coronary stent implantation: a meta-analysis of 5,821 patients.

Drug resistance and secondary treatment of ischaemic stroke: The genetic component of the response to acetylsalicylic acid and clopidogrel.

Standard vs Modified Antiplatelet Preparation for Preventing Thromboembolic Events in Patients With High On-Treatment Platelet Reactivity Undergoing Coil Embolization for an Unruptured Intracranial Aneurysm: A Randomized Clinical Trial.

Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.

P304

207-215

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18999/NAGJMS.80.2.207

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29915438

http://www.w3.org/2001/XMLSchema#string

P921

clopidogrel

P932

5995740

http://www.w3.org/2001/XMLSchema#string